EVALUATION OF EXTENT OF BREAST CANCER IN A PATIENT WITH HER2/NEU OVEREXPRESSION USING A RADIOPHARMACEUTICAL BASED ON TECHNETIUM-99M-LABELED TARGET MOLECULES (CASE REPORT)

Introduction. Overexpression of Her2/neu is detected in 15–20 % of patients with breast cancer and associated with an aggressive form of disease and low overall and disease-free survival rates. Currently, immunohistochemical studies (IHC) and methods of in situ hybridization are used to assess Her2/...

Full description

Bibliographic Details
Main Authors: O. D. Bragina, V. I. Chernov, R. V. Zelchan, A. A. Medvedeva, I. G. Frolova, E. A. Dudnikova, V. E. Goldberg, V. M. Tolmachev
Format: Article
Language:Russian
Published: Russian Academy of Sciences, Tomsk National Research Medical Center 2021-10-01
Series:Сибирский онкологический журнал
Subjects:
Online Access:https://www.siboncoj.ru/jour/article/view/1930